Commentary reveals widespread commercial excess in the pharmaceutical industry, challenging claims of high financial risk.
The main point about excess in the pharmaceutical industry is how much there is of it. Here I can touch on only a few specifics about this altogether over-the-top business. ![Figure][1] Figure. Photo by: Earthlore Although the pharmaceutical industry claims to be a high-risk business,
No takes yet. Share an insight, caveat, or question.
Marcia Angell (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: